Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 18 of 18 entries
Sorted by: Best Match Show Resources per page
Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect.

Journal of drug targeting

Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, García-García A, Villanueva-Olivo A, Rodríguez-Rocha H, Zavala-Flores LM, Saucedo-Cárdenas O, Montes de Oca-Luna R, Loera-Arias MJ.
PMID: 33926356
J Drug Target. 2021 Dec;29(10):1102-1110. doi: 10.1080/1061186X.2021.1919124. Epub 2021 Apr 29.

It has been previously reported that targeting and retaining antigens in the endoplasmic reticulum (ER) can induce an ER stress response. In this study, we evaluated the antitumor effect of E7 antigen fused to an ERresident protein, cyclooxygenase-2, which...

Cite
Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, et al. Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. J Drug Target. 2021;29(10):1102-1110doi: 10.1080/1061186X.2021.1919124.
Martínez-Puente, D. H., Garza-Morales, R., Pérez-Trujillo, J. J., García-García, A., Villanueva-Olivo, A., Rodríguez-Rocha, H., Zavala-Flores, L. M., Saucedo-Cárdenas, O., Montes de Oca-Luna, R., & Loera-Arias, M. J. (2021). Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. Journal of drug targeting, 29(10), 1102-1110. https://doi.org/10.1080/1061186X.2021.1919124
Martínez-Puente, David Hernán, et al. "Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect." Journal of drug targeting vol. 29,10 (2021): 1102-1110. doi: https://doi.org/10.1080/1061186X.2021.1919124
Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, García-García A, Villanueva-Olivo A, Rodríguez-Rocha H, Zavala-Flores LM, Saucedo-Cárdenas O, Montes de Oca-Luna R, Loera-Arias MJ. Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. J Drug Target. 2021 Dec;29(10):1102-1110. doi: 10.1080/1061186X.2021.1919124. Epub 2021 Apr 29. PMID: 33926356.
Copy Download .nbib Format: NLM
Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis.

Molecular neurobiology

Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A.
PMID: 34350555
Mol Neurobiol. 2021 Nov;58(11):5517-5532. doi: 10.1007/s12035-021-02500-z. Epub 2021 Aug 05.

Parkinson's disease (PD) ranks first in the world as a neurodegenerative movement disorder and occurs most commonly in an idiopathic form. PD patients may have motor symptoms, non-motor symptoms, including cognitive and behavioral changes, and symptoms related to autonomic...

Cite
Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, et al. Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. Mol Neurobiol. 2021;58(11):5517-5532doi: 10.1007/s12035-021-02500-z.
Gopar-Cuevas, Y., Duarte-Jurado, A. P., Diaz-Perez, R. N., Saucedo-Cardenas, O., Loera-Arias, M. J., Montes-de-Oca-Luna, R., Rodriguez-Rocha, H., & Garcia-Garcia, A. (2021). Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. Molecular neurobiology, 58(11), 5517-5532. https://doi.org/10.1007/s12035-021-02500-z
Gopar-Cuevas, Yareth, et al. "Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis." Molecular neurobiology vol. 58,11 (2021): 5517-5532. doi: https://doi.org/10.1007/s12035-021-02500-z
Gopar-Cuevas Y, Duarte-Jurado AP, Diaz-Perez RN, Saucedo-Cardenas O, Loera-Arias MJ, Montes-de-Oca-Luna R, Rodriguez-Rocha H, Garcia-Garcia A. Pursuing Multiple Biomarkers for Early Idiopathic Parkinson's Disease Diagnosis. Mol Neurobiol. 2021 Nov;58(11):5517-5532. doi: 10.1007/s12035-021-02500-z. Epub 2021 Aug 05. PMID: 34350555.
Copy Download .nbib Format: NLM
DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect.

Oncology letters

Perez-Trujillo JJ, Garza-Morales R, Barron-Cantu JA, Figueroa-Parra G, Garcia-Garcia A, Rodriguez-Rocha H, Garcia-Juarez J, Muñoz-Maldonado GE, Saucedo-Cardenas O, Montes-De-Oca-Luna R, Loera-Arias MJ.
PMID: 28454292
Oncol Lett. 2017 Mar;13(3):1569-1574. doi: 10.3892/ol.2017.5635. Epub 2017 Jan 23.

Cellular immune responses play a critical role in the eradication of intracellular infections and malignant cells through the recognition and subsequent removal of the infection or malignant cells. Effective antigen presentation is crucial for stimulating the immune system against...

Cite
Perez-Trujillo JJ, Garza-Morales R, Barron-Cantu JA, et al. DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncol Lett. 2017;13(3):1569-1574doi: 10.3892/ol.2017.5635.
Perez-Trujillo, J. J., Garza-Morales, R., Barron-Cantu, J. A., Figueroa-Parra, G., Garcia-Garcia, A., Rodriguez-Rocha, H., Garcia-Juarez, J., Muñoz-Maldonado, G. E., Saucedo-Cardenas, O., Montes-De-Oca-Luna, R., & Loera-Arias, M. J. (2017). DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncology letters, 13(3), 1569-1574. https://doi.org/10.3892/ol.2017.5635
Perez-Trujillo, Jose J, et al. "DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect." Oncology letters vol. 13,3 (2017): 1569-1574. doi: https://doi.org/10.3892/ol.2017.5635
Perez-Trujillo JJ, Garza-Morales R, Barron-Cantu JA, Figueroa-Parra G, Garcia-Garcia A, Rodriguez-Rocha H, Garcia-Juarez J, Muñoz-Maldonado GE, Saucedo-Cardenas O, Montes-De-Oca-Luna R, Loera-Arias MJ. DNA vaccine encoding human papillomavirus antigens flanked by a signal peptide and a KDEL sequence induces a potent therapeutic antitumor effect. Oncol Lett. 2017 Mar;13(3):1569-1574. doi: 10.3892/ol.2017.5635. Epub 2017 Jan 23. PMID: 28454292; PMCID: PMC5403354.
Copy Download .nbib Format: NLM
Correction: Patterns of sedentary behavior in overweight and moderately obese users of the Catalan primary-health care system.

PloS one

Martínez-Ramos E, Beltran AM, Martín-Borràs C, Lasaosa-Medina L, Real J, Trujillo JM, Solà-Gonfaus M, Puigdomenech E, Castillo-Ramos E, Puig-Ribera A, Giné-Garriga M, Serra-Paya N, Rodriguez-Roca B, Gascón-Catalán A, Martín-Cantera C.
PMID: 29590214
PLoS One. 2018 Mar 28;13(3):e0195312. doi: 10.1371/journal.pone.0195312. eCollection 2018.

[This corrects the article DOI: 10.1371/journal.pone.0190750.].

Cite
Martínez-Ramos E, Beltran AM, Martín-Borràs C, et al. Correction: Patterns of sedentary behavior in overweight and moderately obese users of the Catalan primary-health care system. PLoS One. 2018;13(3):e0195312doi: 10.1371/journal.pone.0195312.
Martínez-Ramos, E., Beltran, A. M., Martín-Borràs, C., Lasaosa-Medina, L., Real, J., Trujillo, J. M., Solà-Gonfaus, M., Puigdomenech, E., Castillo-Ramos, E., Puig-Ribera, A., Giné-Garriga, M., Serra-Paya, N., Rodriguez-Roca, B., Gascón-Catalán, A., Martín-Cantera, C. (2018). Correction: Patterns of sedentary behavior in overweight and moderately obese users of the Catalan primary-health care system. PloS one, 13(3), e0195312. https://doi.org/10.1371/journal.pone.0195312
Martínez-Ramos, Elena, et al. "Correction: Patterns of sedentary behavior in overweight and moderately obese users of the Catalan primary-health care system." PloS one vol. 13,3 (2018): e0195312. doi: https://doi.org/10.1371/journal.pone.0195312
Martínez-Ramos E, Beltran AM, Martín-Borràs C, Lasaosa-Medina L, Real J, Trujillo JM, Solà-Gonfaus M, Puigdomenech E, Castillo-Ramos E, Puig-Ribera A, Giné-Garriga M, Serra-Paya N, Rodriguez-Roca B, Gascón-Catalán A, Martín-Cantera C. Correction: Patterns of sedentary behavior in overweight and moderately obese users of the Catalan primary-health care system. PLoS One. 2018 Mar 28;13(3):e0195312. doi: 10.1371/journal.pone.0195312. eCollection 2018. PMID: 29590214; PMCID: PMC5874064.
Copy Download .nbib Format: NLM
An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model.

Vaccines

Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, Ramirez-Avila NE, Loera-Arias MJ, Gomez-Gutierrez JG, Saucedo-Cardenas O, Garcia-Garcia A, Rodriguez-Rocha H, Montes-de-Oca-Luna R.
PMID: 33673295
Vaccines (Basel). 2021 Feb 12;9(2). doi: 10.3390/vaccines9020149.

Human papillomaviruses (HPVs) are responsible for about 25% of cancer cases worldwide. HPV-16 E7 antigen is a tumor-associated antigen (TAA) commonly expressed in HPV-induced tumors; however, it has low immunogenicity. The interaction of 4-1BBL with its receptor induces pleiotropic...

Cite
Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, et al. An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines (Basel). 2021;9(2)doi: 10.3390/vaccines9020149.
Martinez-Perez, A. G., Perez-Trujillo, J. J., Garza-Morales, R., Ramirez-Avila, N. E., Loera-Arias, M. J., Gomez-Gutierrez, J. G., Saucedo-Cardenas, O., Garcia-Garcia, A., Rodriguez-Rocha, H., & Montes-de-Oca-Luna, R. (2021). An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines, 9(2), . https://doi.org/10.3390/vaccines9020149
Martinez-Perez, Alejandra G, et al. "An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model." Vaccines vol. 9,2 (2021). doi: https://doi.org/10.3390/vaccines9020149
Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, Ramirez-Avila NE, Loera-Arias MJ, Gomez-Gutierrez JG, Saucedo-Cardenas O, Garcia-Garcia A, Rodriguez-Rocha H, Montes-de-Oca-Luna R. An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines (Basel). 2021 Feb 12;9(2). doi: 10.3390/vaccines9020149. PMID: 33673295; PMCID: PMC7917608.
Copy Download .nbib Format: NLM
Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect.

Journal of drug targeting

Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, García-García A, Villanueva-Olivo A, Rodríguez-Rocha H, Zavala-Flores LM, Saucedo-Cárdenas O, Montes de Oca-Luna R, Loera-Arias MJ.
PMID: 33926356
J Drug Target. 2021 Dec;29(10):1102-1110. doi: 10.1080/1061186X.2021.1919124. Epub 2021 Apr 29.

It has been previously reported that targeting and retaining antigens in the endoplasmic reticulum (ER) can induce an ER stress response. In this study, we evaluated the antitumor effect of E7 antigen fused to an ERresident protein, cyclooxygenase-2, which...

Cite
Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, et al. Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. J Drug Target. 2021;29(10):1102-1110doi: 10.1080/1061186X.2021.1919124.
Martínez-Puente, D. H., Garza-Morales, R., Pérez-Trujillo, J. J., García-García, A., Villanueva-Olivo, A., Rodríguez-Rocha, H., Zavala-Flores, L. M., Saucedo-Cárdenas, O., Montes de Oca-Luna, R., & Loera-Arias, M. J. (2021). Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. Journal of drug targeting, 29(10), 1102-1110. https://doi.org/10.1080/1061186X.2021.1919124
Martínez-Puente, David Hernán, et al. "Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect." Journal of drug targeting vol. 29,10 (2021): 1102-1110. doi: https://doi.org/10.1080/1061186X.2021.1919124
Martínez-Puente DH, Garza-Morales R, Pérez-Trujillo JJ, García-García A, Villanueva-Olivo A, Rodríguez-Rocha H, Zavala-Flores LM, Saucedo-Cárdenas O, Montes de Oca-Luna R, Loera-Arias MJ. Targeting E7 antigen to the endoplasmic reticulum degradation pathway promotes a potent therapeutic antitumor effect. J Drug Target. 2021 Dec;29(10):1102-1110. doi: 10.1080/1061186X.2021.1919124. Epub 2021 Apr 29. PMID: 33926356.
Copy Download .nbib Format: NLM
Showing 13 to 18 of 18 entries